Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with
pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant
melanoma in stage IIA (T3a) - IIIB.
A total of 880 will be randomized up to three months after first surgical management of their
melanoma to either: PEG-IFN-α-2a or low-dose interferon-α-2a.